Abstract
Interleukin 21 (IL-2) is a 15 kD protein that was initially known as T-cell growth factor [1], IL-2 stimulates the proliferation of T cells both in vitro and in vivo. Incubation of lymphocytes with IL-2 in vitro results in the generation of cells referred to as lymphokine activated killer (LAK) cells, which lyse fresh noncultured tumor cells in a histocompatibility unrestricted manner [2–4]. LAK cells show killing effects both in vitro and in vivo of a wide variety of tumors [2–4]. Recent studies [5,6] have shown that LAK cells are comprised of T cells as well as natural killer (NK) cells. Other cells, such as macrophages, probably also play a role in regulating the generation of LAK cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Smith KA: Interleukin-2: Inception, impact, and implications. Science 240:1169–1176, 1988.
Lotze MT, Line BR, Mathisen DJ, et al.: The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implication for the adoptive immunotherapy of tumors. J Immunol 125:1487–1493, 1980.
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841, 1982.
Rayner AA, Grimm EA, Lotze MT, et al.: Lymphokine activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 75:67–75, 1985.
Kalland T, Belfrage H, Bhiladvala P, Hedlund G: Analysis of the murine lymphokine activated killer (LAK) cell phenomenon: Dissection of effectors and progenitors into NK-and T-like cells. J Immunol 138:3640–3645, 1987.
Chadwick BS, Miller RG: Heterogeneity of the lymphokine-activated killer cell phenotype. Cell Immunol 132:168–176, 1991.
Lotze MT, Chang AE, Seipp CA, Simpson CG, Vetto JT, Rosenberg SA: High dose recombinant-2 in the treatment of patients with disseminated cancer. JAMA 256:3117–3124, 1986.
Rosenberg SA, Lotze MT, Yang JC, et al.: Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474–485, 1989.
Agah R, Malloy B, Sherrod A, Mazumder A: Successful therapy of natural killer-resistant pulmonary metastases by the synergism of γ-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res 48:2245–2248, 1988.
Ettinghausen SE, Lipford EH, Mule JJ, et al.: Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol 135: 1488–1497, 1985.
Ettinghausen SE, Lipford EH, Mule JJ, et al.: Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine activated killer (LAK) cells. J Immunol 135:3623–3635, 1985.
Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199, 1992.
Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT: Immunohistochemical correlates of response to IL-2 based immunotherapy in humans. Cancer Res 49:7086–7092, 1989.
McCulloch P, Gallagher G, Walsh LP, Zaloom Y, Xie J: Lymphokine-activated killer (LAK) cells modulate the effects IL-2 on a T cell mediated immune response. Clin Exp Immunol 85:519–524, 1991.
Papa MZ, Yang JC, Vetto JT, et al.: Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 48:122–129, 1988.
Charak BS, Brynes RK, Groshen S, Chen S-C, Mazumder A: Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76:2187–2190, 1990.
Hamon MD, Prentice HG, Gottlieb DJ, et al.: Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 11:399–401, 1993.
Favrot MC, Floret D, Negrier S, et al.: Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 4:499–503, 1989.
Gottlieb DJ, Brenner MK, Heslop HE, et al.: A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for hematological malignancy: Applicability to the elimination of minimal residual disease. Br J Cancer 60:810–816, 1990.
Blaise D, Olive D, Stoppa AM, et al.: Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 76:1092–1097, 1990.
Higuchi CM, Thompson JA, Peterson FB, Buckner CD, Fefer A: Toxicity and immuno-modulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologie malignancies. Blood 77:2561–2568, 1991.
Soiffer RJ, Murray C, Cochran K, et al.: Clinical and immunologie effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79:517–526, 1992.
Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB: Interleukin-2 induction of lymphokine-activated killer (LAK) cell activity in the peripheral blood and bone marrow of acute leukemia patients: I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:706–716, 1988.
Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA: Eradication of disseminated murine leukemia by treatment with high dose interleukin-2. J Immunol 137:3675–3680, 1986.
Charak BS, Brynes RK, Chogyoji M, Mazumder A: Lymphokine-activated killer cells in autologous bone marrow transplantation. Evidence against inhibition of engraftment in vivo. Transplantation 54:1008–1013, 1992.
Foa R, Meloni G, Tosti S, et al.: Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): Clinical and biological findings. Bone Marrow Transplant 6(Suppl l):98–102, 1990.
Komori T, Sugiyama H, Ogawa H, et al.: Treatment of a patient in a relapse after bone marrow transplantation for acute lymphoblastic leukemia with the systemic administration of allogeneic lymphokine activated killer cells and recombinant IL-2. Eur J Haematol 43:184–185, 1989.
Dickinson AM, Lennard AL, Cartner R, Proctor SJ: Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukemia patient — case study. Leukemia 6:957–960, 1992.
Weisdorf DJ, Anderson PM, Blazar BR, Uckun FM, Kersey JH, Ramsay NKC: Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia — a phase I study. Transplantation 55:61–66, 1993.
Papa MZ, Mule JJ, Rosenberg SA: Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer Res 46:4973–4978, 1986.
Peace DJ, Cheever MA: Toxicity and therapeutic efficacy of high dose interleukin-2. In vivo infusion of an antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 169:161–173, 1989.
Fefer A, Benyunes M, Higuchi C, York A, Massumoto C, Lingren C, Buckner CD, Thompson JA: Interleukin-2 ± lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologie malignancies. Acta Hematol 89(Suppl l):2–7, 1993.
Benyunes MC, Massumoto C, York A, et al.: Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12:159–163, 1993.
Fujimori Y, Hara H, Nagai K: Effect of lymphokine activated killer cell fraction on the development of human hematopoietic progenitor cells. Cancer Res 48:534–538, 1987.
van den Brink MRM, Voogt PJ, Marijt WAF, van Luxemburg-Heys SAP, Van Rood JJ, Brand AA: Lymphokine activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 74:354–560, 1989.
Charak BS, Malloy B, Agah R, Mazumder A: A novel approach to purging of leukemia by activation of bone marrow with interleukin-2. Bone Marrow Transplant 6:193–198, 1990.
Schaafsma MR, Fibbe WE, van der Harst D, et al.: Increased numbers of circulating hematopoietic progenitor cells after treatment with high dose interleukin-2 in cancer patients. Br J Haematol 76:180–185, 1990.
Heslop HE, Bello-Fernandez C, Reittie JE, et al.: Interleukin 2 infusion after autologous bone marrow transplantation or chemotherapy enhances hematopoietic regeneration. Blood 76(Suppl 1):544, 1990.
Bosly AC, Staquet PJ, Doyen CM, Chatelain BJ, Humblet YP, Symann ML: Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation. Exp Hematol 15:1048–1054, 1987.
Borradori L, Hirt A, Baumgartner C, Morell A: Influence of exogenous interleukin-2 on the proliferation of lymphocytes from normal donors and from patients after autologous bone marrow transplantation. Acta Haematol 77:129–134, 1987.
Reittie JE, Gottlieb D, Heslop HE, et al.: Endogenously generated killer cells circulate after autologous and allogeneic bone marrow transplantation but not after chemotherapy. Blood 73:1341–1358, 1989.
Bosly A, Guillame T, Brice P, et al.: Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp Hematol 20:962–968, 1992.
Heslop HE, Gottlieb DJ, Bianchi ACM, et al.: In vivo induction of y interferon and tumor necrosis factor by interleukin-2 infusin following intensive chemotherapy or autologous bone marrow transplantation. Blood 74:1374–1380, 1989.
Massumoto C, Sale G, Benyunes M, et al.: Cutaneous GVHD associated with IL-2 + LAK therapy after autologous bone marrow transplantation (ABMT) for hematologic malignancies. Proc Am Soc Clin Oncol 11:825, 1992.
Sprent J, Schaefer M, Gao E, Korngold R: Role of T cell subsets in lethal graft versus host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts. J Exp Med 167:556–569, 1988.
Malkovsky M, Brenner MK, Hunt R, et al.: T cell depletion of allogeneic bone marrow prevents acceleration of graft versus host disease induced by exogenous IL-2. Cell Immunol 103:476–480, 1986.
Sykes M, Abraham BS, Harty MW, Pearson DA: IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 150:197–205, 1993.
Sykes M, Harty MW, Szot GL, Pearson DA: Interleukin-2 inhibits graft versus host disease promoting activity of CD4+ cells while preserving CD4¯ and CD8¯ mediated graft versus leukemia effects. Blood 83:2560–2569, 1994.
Azuma E, Kaplan J: Role of lymphokine-activated killer cells as mediators of veto and natural suppression. J Immunol 141:2601–2606, 1988.
Nakamura H, Gress RE: Interleukin-2 enhancement of veto suppressor cell function in T-cell-depleted bone marrow in vitro and in vivo. Transplantation 49:931–937, 1990.
Sykes M, Romick ML, Sachs DH: Interleukin-2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 87:5633–5637, 1990.
Margolin K: The clinical toxicities of high-dose interleukin-2: In Atkins MB, Mier JW (eds): Therapeutic Applications of Interleukin-2. Marcel Dekker, New York: pp 331–362.
Damle NK, Doyle LV, Bender JR, Bradley EC: Interleukin-2 activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 138:1779–1785, 1987.
Thompson JA, Biance JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A: Phase Ib trial of pertoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res 54:3436–3441, 1994.
Numerof RP, Aronson FR, Mier JW: Interleukin-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol 141:4250–4557, 1988.
Mier JW, Vachino G, Van der Meer J, et al.: Induction of tumor necrosis factor as the mechanism for the febrile response to interleukin-2. J Clin Immunol 8:426–436, 1988.
Vachino G, Gelfand J, Atkins M, Tamerius J, Demchak P, Mier J: Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): Binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 78:2505–2513, 1991.
Gribben JG, Freedman AS, Neuberg D, et al.: Immunological purging of marrow assessed by PCR before autologous bone marrow transplantation for B cell lymphoma. N Engl J Med 325:1525–1533, 1991.
Ringden O, Horowitz MM: Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. Transplant Proc 21:2989–2992, 1989.
Rosenfeld C, Shadduck RK, Przepiorka D, Mangan KF, Colvin M: Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for acute nonlymphocytic leukemia in late remission or early relapse. Blood 74:1159–1164, 1989.
Pole JG, Gee A, Jansen W, Lee C, Gross S: Immunomagnetic purging of bone marrow: A model for negative cell selection. Am J Pediatr Hematol Oncol 12:257–261, 1990.
Vogler WR, Berdel WE, Olson AC, Winton EF, Heffner LT, Gordon DS: Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyllysophos-pholipids. Blood 80:1423–1429, 1992.
Brenner MK, Rill DR, Moen RC, et al.: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85–86, 1993.
Uckum FM, Kersey JH, Vallera DA, et al.: Autologous bone marrow transplantation in high risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 76:1723–1733, 1990.
Truitt RL, Horowitz MM, Atasoylu AA, Drobyski WR, Johnson BD, LeFever AV: Graft-versus-leukemia effect of allogeneic bone marrow transplantation: Clinical and experimental aspects of late leukemia relapse. In Stewart THM, Wheelock EF (eds): Cellular Immune Mechanisms and Tumor Dormancy. Boca Raton, FL: CRC Press, PP 111–128, 1992.
Horowitz MM, Gale RP, Sondel PM, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555–562, 1990.
Chang WC, Hsiao MH, Pattengale PK: Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor. Nat Immun Cell Growth Regul 10:57–70, 1991.
Mackinnon S, Hows JM, Goldman JM: Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myelogenous leukemia. Blood 76: 2037–2045, 1990.
Hauch M, Gazzola MV, Small T, et al.: Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250–2262, 1990.
Agah R, Malloy B, Kerner M, Mazumder A: Generation and characterization of IL-2 activated bone marrow cells as a potent graft versus tumor effector in transplantation. J Immunol 143:3039–3099, 1989.
Charak BS, Brynes RK, Katsuda S, Groshen S, Chen S-C, Mazumder A: Induction of graft versus leukemia effect in bone marrow transplantation: Dosage and time schedule dependency of interleukin-2 therapy. Cancer Res 51:2015–2020, 1991.
Charak BS, Agah R, Gray D, Mazumder A: Interaction of various cytokines with interleukin-2 in the generation of killer cells from human bone marrow: Application in purging of leukemia. Leuk Res 15:801–810, 1991.
Keever CA, Pekle K, Gazzola MV, Collins NH, Gillio A: NK and LAK activities from human bone marrow progenitors. I. The effects of interleukin-2 and interleukin-1. Cell Immunol 126:211–226, 1990.
Agah R, Malloy B, Kerner M, Girgis E, Bean P, Twomey P, Mazumder A: Potent graft anti-tumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin-2-activated syngeneic bone marrow in mice. Cancer Res 49:5959–5963, 1989.
Lotze MT, Matory YL, Ettinghausen SE, et al.: In vivo administration of purified human interleukin-2: Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135: 2865–2875, 1985.
Kedar E, Klein E: Cancer immunotherapy: Are the results discouraging? Can they be improved? Adv Cancer Res 59:245–322, 1992.
Mitchell MS: Combining chemotherapy with biological response modifiers in the treatment of cancer. J Natl Cancer Inst 8:1445–1450, 1988.
Charak BS, Brynes RK, Chogyoji M, Kortes V, Tefft M, Mazumder A: Graft versus leukemia effect of interleukin-2-activated bone marrow: Correlation with eradication of residual disease. Transplantation 56:31–37, 1993.
Charak BS, Agah R, Brynes RK, Chogyoji M, Groshen S, Chen S-C, Mazumder A: Interleukin-2 (IL-2) and IL-2-activated done marrow in transplantation: Evaluation from a clinical perspective. Bone Marrow Transplant 9:479–486, 1992.
Coulombel L, Kalousek D, Eaves CJ, Gupta CM, Eaves A: Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 308:1493–1498, 1983.
Hogge DE, Coulombel L, Kalousek DK, Eaves CJ, Eaves AC: Nonclonal hemopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol 24:389–394, 1987.
Coulombel L, Eaves CJ, Kalousek DK, Gupta C, Eaves AC: Long term marrow culture of cells from patients with acute myelogenous leukemia. J Clin Invest 75:961–969, 1985.
Firkin FC, Birner R, Farag S: Differential action of diffusible molecules in long term culture on proliferation of leukemic and normal hematopoietic cells. Br J Hematol 84:8–15, 1993.
Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC: Rapid decline of chronic myeloid leukemic cells in long term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 89:6192–6196, 1992.
Lotzova E, Savary CA: Generation of NK cell activity from human bone marrow. J Immunol 139:279–284, 1987.
Verma UN, Bagg A, Brown E, Mazumder A: Interleukin-2 activation of human bone marrow in long term cultures: An effective strategy for purging and generation anti-tumor cytotoxic effectors. Bone Marrow Transplant 13:115–123, 1994.
Savary CA, Lotzova E: Inhibition of human bone marrow and myeloid progenitors by interleukin-2 activated lymphocytes. Exp Hematol 18:1083–1089, 1990.
Cuturi MC, Anegon I, Sherman F, et al.: Production of hematopoietic colony-stimulating factors by human natural killer cells. J Exp Med 169:569–583, 1989.
Murphy WJ, Keller JR, Harrison CL, Young HA, Longo DL: Interleukin-2 activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 80:670–677, 1992.
Verma UN, Mazumder A: Purging and hematopoietic reconstitution ability of murine bone marrow IL-2 activated in long term cultures. Manuscript in preparation.
Klingemann HG, Deal H, Reid D, Eaves CJ: Pre-clinical evaluation of a bone marrow autograft culture procedure for generating lymphokine-activated killer cells in vitro. Can J Infect Dis 3:123B-127B, 1992.
Klingemann HG, Deal H, Reid D, Eaves CJ: Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 21:1263–1270, 1993.
Long GS, Cramer DV, Harnaha JB, Hiserodt JC: Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: Range of activity against different hematopoietic neoplasms. Bone Marrow Transplant 6:169–177, 1990.
Chao N, Schriber J, Grimes K, et al.: Granulocyte colony-stimulating factor ‘mobilized’ peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high dose chemotherapy. Blood 81:2031–2035, 1993.
To LB, Roberts MM, Haylock DN, et al.: Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell Transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9:277–284, 1992.
Kessinger A, Armitage JO: The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 77:211–213, 1991.
Kessinger A, Bierman P, Vose J, Armitage JO: High-dose cyclophosphamide, carmustine, and etopside followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin’s disease. Blood 77:2322–2325, 1991.
Liu K-Y, Akashi K, Harada M, Takamatsu Y, Niho Y: Kinetics of circulating hematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol 84:31–38, 1993.
Verma UN, Areman E, Dickerson SA, Kotula PL, Sacher R, Mazumder A: Interleukin-2 activation of chemotherapy and growth factor mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant 15:199–206, 1995.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Verma, U.N., Charak, B.S., Rajagopal, C., Mazumder, A. (1995). Interleukin-2 in Bone Marrow Transplantation. In: Buckner, C.D., Clift, R.A. (eds) Technical and Biological Components of Marrow Transplantation. Cancer Treatment and Research, vol 76. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2013-9_15
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2013-9_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5832-9
Online ISBN: 978-1-4615-2013-9
eBook Packages: Springer Book Archive